Suzanne E. Schindler, Julia D. Gray, Brian A

Slides:



Advertisements
Similar presentations
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Advertisements

Date of download: 6/23/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Pulse Pressure in Relation to Tau-Mediated Neurodegeneration,
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduction of SorLA/LR11, a Sorting Protein Limiting.
Are early atrophy patterns in autosomal dominant familial Alzheimer's disease gene- dependent?  Kirsi Kinnunen, Natalie Ryan, David Cash, António Bastos.
Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study  Wesley.
Journal of the Neurological Sciences
Volume 3, Issue 1, Pages (January 2017)
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Hilkka Liedes, Jyrki Lötjönen, Gerald P. Novak, Mark Forrest Gordon 
Early pathologic amyloid induces hypersynchrony of BOLD resting-state networks in transgenic mice and provides an early therapeutic window before amyloid.
Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease  Azadeh Karami, Helga Eyjolfsdottir, Swetha.
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 1, Issue 3, Pages (November 2015)
Type II collagen C2C epitope in human synovial fluid and serum after knee injury – associations with molecular and structural markers of injury  N. Kumahashi,
Dement Geriatr Cogn Disord Extra 2014;4: DOI: /
Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints  Argonde C. van Harten, Pieter Jelle Visser,
Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design  Arno de Wilde, Ingrid S. van Maurik, Marleen Kunneman, Femke Bouwman, Marissa.
SMARTPHONE TECHNOLOGY TO MEASURE HEALTH CHARACTERISTICS IN OFFSPRING OF PATIENTS WITH DEMENTIA: THE IVITALITY PROOF-OF- PRINCIPLE STUDY  Liselotte Wijsman,
KETOGENIC DIET EFFECTS ON BRAIN KETONE METABOLISM AND ALZHEIMER'S DISEASE CSF BIOMARKERS  Suzanne Craft, Bryan J. Neth, Akiva Mintz, Kiran Sai, Nora Shively,
An amylin analog used as a challenge test for Alzheimer's disease
A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission.
Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment  Sanna-Kaisa Herukka,
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 2, Issue 1, Pages (January 2016)
Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin  Eva Carro, Fernando Bartolomé, Félix Bermejo-Pareja,
Volume 17, Issue 3, Pages (March 2018)
Separate Quality-Control Measures Are Necessary for Estimation of RNA and Methylated DNA from Formalin-Fixed, Paraffin-Embedded Specimens by Quantitative.
An ARGS-aggrecan assay for analysis in blood and synovial fluid
The component-specific to total IgE ratios do not improve peanut and hazelnut allergy diagnoses  Linus Grabenhenrich, MD, MPH, Lars Lange, MD, Magdalena.
Volume 67, Issue 6, Pages (June 2015)
Volume growth of abdominal aortic aneurysms correlates with baseline volume and increasing finite element analysis-derived rupture risk  Moritz Lindquist.
Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry.
Anahita Dua, MD, MS, MBA, Gilbert R. Upchurch, MD, Jason T
Blood pressure monitoring during arrhythmia: agreement between automated brachial cuff and intra-arterial measurements  K. Lakhal, S. Ehrmann, M. Martin,
Tiina Annus, Liam R. Wilson, Young T
Advances in the War on Alzheimer's
Biomarker Modeling of Alzheimer’s Disease
Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.
Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study  Kumar B. Rajan, Jennifer Weuve,
Volume 78, Issue 2, Pages (April 2013)
In vivo tau imaging: Obstacles and progress
C.C. Apfel, P. Kranke, C.-A. Greim, N. Roewer 
A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis  Caitlin S. Latimer, Carol A. Shively,
Volume 17, Issue 3, Pages (March 2018)
Clifford R. Jack, Heather J. Wiste, Stephen D. Weigand, Terry M
Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study  Kumar B. Rajan, Jennifer Weuve,
Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity  Severine Vermeire, Stefan Schreiber,
Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease  Antoine Leuzy, Elena Rodriguez-Vieitez,
The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability.
Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective  Matthew Baumgart, Heather M. Snyder,
Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision.
A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42  Kristel Sleegers,
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study  Osama Sabri, Marwan N. Sabbagh, John Seibyl, Henryk Barthel,
Shruti Mishra, Brian Andrew Gordon, Karl A
Comparison of visual and quantitative florbetapir-PET reads in subjects with early Alzheimer's disease for assessing amyloid burden  Bradley Wyman, Yahong.
Massimo S. Fiandaca, Mark E. Mapstone, Amrita K. Cheema, Howard J
Added value of 11C-PiB-PET imaging in the diagnosis of Alzheimer's disease  Kristian Frederiksen, Anne-Mette Hejl, Ian Law, Steen Hasselbalch, Gunhild.
H. Solus-Biguenet, M. Fleyfel, B. Tavernier, E. Kipnis, J. Onimus, E
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people  Oskar Hansson, Sebastian Palmqvist,
DIFFERENCES IN ANALYTICAL SELECTIVITY OF β-AMYLOID (1-42) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS  Hugo Marcel Vanderstichele, Emeric.
Intersite variability of CSF Alzheimer’s disease biomarkers in clinical setting  Julien Dumurgier, Olivier Vercruysse, Claire Paquet, Stéphanie Bombois,
Fig. 1. AD biomarker levels in the cerebrospinal fluid of iNPH, AD, and CN subjects. Box plots of Aβ42 (A), Aβ40 (B), Aβ42/Aβ40 ratio (C), t-tau (D),
A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis  Caitlin S. Latimer, Carol A. Shively,
Michael Navitsky, Abhinay D. Joshi, Michael D. Devous, Michael J
Figure 2 Aβ-PET scans obtained using different tracers
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER.
CESD: Center for Epidemiologic Studies Depression.
Presentation transcript:

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging  Suzanne E. Schindler, Julia D. Gray, Brian A. Gordon, Chengjie Xiong, Richard Batrla-Utermann, Marian Quan, Simone Wahl, Tammie L.S. Benzinger, David M. Holtzman, John C. Morris, Anne M. Fagan  Alzheimer's & Dementia: The Journal of the Alzheimer's Association  Volume 14, Issue 11, Pages 1460-1469 (November 2018) DOI: 10.1016/j.jalz.2018.01.013 Copyright © 2018 The Authors Terms and Conditions

Fig. 1 Single CSF analyte values compared to PIB binding. PIB binding was negatively correlated with CSF Aβ42 (A) and positively correlated with CSF Aβ40 (B), tTau (C), and pTau (D). Each point represents the analyte value and PIB mean cortical SUVR for one individual. The horizontal red dashed lines represent the cutoff values that best distinguish between PIB-positive and PIB-negative individuals. The horizontal gray dotted line represents the upper limit of quantitation for Aβ42 (A). For the upper panels, the vertical red dashed lines represent the established cutoff value for PIB positivity (SUVR > 1.42). The Spearman correlation coefficient (r) with 95% confidence intervals is indicated. For the lower panels, individuals were dichotomized into PIB-negative (SUVR ≤ 1.42) and PIB-positive (SUVR > 1.42) groups. The lower panels indicate the cutoff values and associated positive percent agreement (PPA), negative percent agreement (NPA), and overall percent agreement (OPA) for each CSF analyte with PIB binding. Abbreviations: CSF, cerebrospinal fluid; PIB, Pittsburgh Compound B; tTau, total tau; pTau, phosphorylated tau-181; Aβ42, amyloid β peptide 42; SUVR, standardized uptake value ratio. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2018 14, 1460-1469DOI: (10.1016/j.jalz.2018.01.013) Copyright © 2018 The Authors Terms and Conditions

Fig. 2 CSF ratios compared to PIB binding. PIB binding is positively correlated with CSF tTau/Aβ42 (A), pTau/Aβ42 (B), and Aβ42/Aβ40 (C). Each point represents the ratio of analytes and PIB mean cortical SUVR for one individual. The horizontal red dashed lines represent the cutoff values that best distinguish between PIB-positive and PIB-negative individuals. For the upper panels, the vertical red dashed lines represent the established cutoff value for PIB positivity (SUVR > 1.42). The Spearman correlation coefficient (r) with 95% confidence intervals is indicated. For the lower panels, individuals were dichotomized into PIB-negative (SUVR ≤ 1.42) and PIB-positive (SUVR > 1.42) groups. The lower panels indicate the cutoff values and associated positive percent agreement (PPA), negative percent agreement (NPA), and overall percent agreement (OPA) for each CSF analyte with PIB binding. Abbreviations: CSF, cerebrospinal fluid; PIB, Pittsburgh Compound B; tTau, total tau; pTau, phosphorylated tau-181; Aβ42, amyloid β peptide 42; SUVR, standardized uptake value ratio. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2018 14, 1460-1469DOI: (10.1016/j.jalz.2018.01.013) Copyright © 2018 The Authors Terms and Conditions

Fig. 3 Receiver operator characteristic (ROC) curves for CSF biomarkers compared to PIB binding. For ROC analysis, individuals were dichotomized into PIB-negative (SUVR ≤ 1.42) and PIB-positive (SUVR > 1.42) groups. For each CSF biomarker measure, the table indicates the cutoff values and associated positive percent agreement (PPA), negative percent agreement (NPA), and area under the ROC curve (AUC) for the measure compared to PIB status. 95% confidence intervals are included in parentheses. Abbreviations: CSF, cerebrospinal fluid; PIB, Pittsburgh Compound B; SUVR, standardized uptake value ratio. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2018 14, 1460-1469DOI: (10.1016/j.jalz.2018.01.013) Copyright © 2018 The Authors Terms and Conditions

Fig. 4 Concordance of CSF ratios and PIB binding. The status (positive or negative according to CSF ratios or PIB binding) was evaluated in scatterplots of CSF tTau versus Aβ42 (A), pTau versus Aβ42 (B), and Aβ40 versus Aβ42 (C). Each point represents CSF biomarkers in one individual. Solid points have a positive biomarker status (as defined in the plot titles) and open points have a negative status. The horizontal red dashed lines represent the cutoff values for CSF tTau (A), pTau (B), and Aβ40 (C). The vertical red dashed lines represent the cutoff value for Aβ42. The vertical gray dotted lines represent the upper limit of quantitation for Aβ42. The sloped solid red lines represent the cutoff values for tTau/Aβ42 (A), pTau/Aβ42 (B), and Aβ40/Aβ42 (C). Abbreviations: CSF, cerebrospinal fluid; PIB, Pittsburgh Compound B; tTau, total tau; pTau, phosphorylated tau-181; Aβ42, amyloid β peptide 42. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2018 14, 1460-1469DOI: (10.1016/j.jalz.2018.01.013) Copyright © 2018 The Authors Terms and Conditions